/KYMR

Kymera Therapeutics Inc

KYMR

$114.96USD↓-1.74%-2.04 today

MARKET CAP

9.6B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$114 – $120

52W RANGE

$44

$130

AI Summary

Stalk

Sell NowMedium

KYMR is in Stage 3 distribution with active lower highs & lower lows pattern, confirming medium-term bearish bias. Short-term weakness at EMAs favors selling into rallies with price below declining 9/20 EMAs and 50 SMA, but long-term trend remains supported by the 200-day SMA. We will sell now into resistance around the 20-day EMA and prior swing highs.

↑Q2 collaboration revenue $65M, beating $32.8M estimate driven by Gilead and Sanofi milestones
↑KT-621 Phase 2b atopic dermatitis enrollment completed six months early; top-line data by year-end 2026
↓Negative profitability and earnings yield highlight inefficient capital returns

Full analysis →

Buying

7

institutions

Selling

3

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
TR T. Rowe Price Investment Management, Inc. Q2 2026	BUY	6.26 M	717.52 M	+792.26 K	+57.6%	0.47%
BI Blackrock, Inc. Q2 2026	BUY	5.54 M	635.07 M	+477.33 K	+50.7%	0.01%
WP Woodline Partners LP Q2 2026	BUY	500.87 K	57.43 M	+93.70 K	+69.4%	0.18%
CA Citadel Advisors LLC Q2 2026	BUY	174.96 K	20.06 M	+19.26 K	+54.7%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	113.06 K	12.63 M	+-12.36 K	+26.7%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	31.37 K	3.60 M	+-1.00 K	+33.4%	0.01%
JH Janus Henderson Group Plc Q1 2026	BUY	42.12 K	3.51 M	+21.06 K	+114.2%	0.00%
MG Man Group Plc Q2 2026	BUY	19.09 K	2.19 M	+5.75 K	+97.1%	0.00%
FA Fisher Asset Management, LLC Q2 2026	BUYNEW	12.73 K	1.46 M	+12.73 K	+0.0%	0.00%
AC Aqr Capital Management LLC Q2 2026	SELL	9.54 K	1.09 M	+-6.41 K	-17.6%	0.00%